News Conference News ESC 2023 New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground Caitlin E. Cox August 30, 2023
Presentation ESC 2023 DICTATE AHF: Efficacy and Safety of Dapagliflozin in Acute Heart Failure Presenter: Zachary Cox August 28, 2023
News Conference News ESC 2023 STEP-HFpEF: Semaglutide Cuts Weight and Symptoms, Boosts Function Shelley Wood August 25, 2023
News Daily News SGLT2i May Be Helpful Early After Acute MI in Diabetic Patients Todd Neale July 17, 2023
News Daily News Congestion Biomarker CA125 Signals Worse Outcomes in Ambulatory HFrEF Todd Neale July 03, 2023
News Daily News New Expert Consensus Papers Aim to Boost Management, Outcomes in HFpEF L.A. McKeown April 19, 2023
News Daily News AHA/ACC Scientific Statement Supports Exercise Therapy in HFpEF L.A. McKeown March 27, 2023
News Daily News Borderline Cost-effectiveness for SGLT2 Inhibitors in HFpEF Todd Neale March 15, 2023
News Conference News ACC 2023 How Dapagliflozin Works in HFpEF: Some Clues From CAMEO-DAPA Todd Neale March 09, 2023
News Daily News HFrEF’s Financial Burden May Get Relief From Inflation Reduction Act L.A. McKeown January 13, 2023
News Daily News Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths Michael O'Riordan December 08, 2022
News Conference News AHA 2022 EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD Todd Neale November 06, 2022
News Conference News HFSA 2022 New Dapagliflozin Insights: Early Benefits and Types of Deaths Prevented Todd Neale October 07, 2022
News Conference News HFSA 2022 Dapagliflozin’s Benefits Similar in HF Patients With Improved EF: DELIVER Todd Neale October 04, 2022
News Conference News ESC 2022 DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum Todd Neale August 27, 2022
News Opinion Editor's Corner ESC 2022 What’s Going to Be Hot at ESC 2022? Shelley Wood August 22, 2022